Company intelligence / Profile preview

Immitra Bio

Schlieren, Zurich, Switzerlandimmitrabio.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Immitra Bio has developed a proprietary gene-integration platform, HematoGen, which combines CRISPR-Cas9 gene editing with hematopoietic stem cell technology to enable precise and durable correction of genetic defects in blood stem cells. The company’s approach aims for lifelong therapeutic benefit by addressing the root cause of rare genetic diseases. Their programs are currently at the pre-clinical stage and focus on haemoglobinopathies such as beta-thalassemia and alpha-thalassemia[1][4].

Therapeutic areas: Rare DiseasesHematology
Modalities: Gene editingCell therapyCRISPR-Cas9Hematopoietic Stem Cells (HSCs)
Industry: Biotech

Partnerships

Ariya Bio (collaborative focus on hereditary blood diseases)[4]

Beyond the preview

Go deeper on Immitra Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Immitra Bio.

Explore the full profile